Similarly, the results of another study demonstrated different levels of detection of the KRAS mutation in the same plasma samples between two platforms, OncoBEAMTM RAS CRC and IdyllaTM ctKRAS Mutation Test. This evidence concerns the gene KRAS and colorectal carcinoma.